Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

255

Participants

Timeline

Start Date

November 21, 2019

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2027

Conditions
Acute Myeloid LeukemiaAcute Lymphoid LeukemiaMyelodysplastic SyndromesAcute LeukemiaBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Chronic Myeloid Leukemia
Interventions
BIOLOGICAL

Orca-T

an allogeneic stem cell and T-cell immunotherapy biologic

Trial Locations (21)

10021

Weill Cornell Medicine - New York-Presbyterian Hospital, New York

10065

Memorial Sloan Kettering Cancer Center, New York

30322

Winship Cancer Institute - Emory University, Atlanta

33136

University of Miami Hospital and Clinics - Sylvester Comprehensive Cancer Center, Miami

33612

Moffitt Cancer Center, Tampa

37203

Sarah Cannon Research Institute, Nashville

37232

Vanderbilt University, Nashville

44195

Cleveland Clinic, Cleveland

48109

University of Michigan Health System - Michigan Medicine, Ann Arbor

60637

University of Chicago, Chicago

66160

The University of Kansas Hospital, Kansas City

73104

OU Health Stephenson Cancer Center, Oklahoma City

77054

University of Texas MD Anderson Cancer Center, Houston

80218

Colorado Blood Cancer Institute, Denver

84112

University of Utah - Huntsman Cancer Institute, Salt Lake City

90095

Ronald Reagan UCLA Medical Center, Los Angeles

91010

City of Hope, Duarte

94305

Stanford Health Care, Stanford

95817

UC Davis, Sacramento

97239

Oregon Health & Sciences University - Knight Cancer Institute, Portland

02114

Massachusetts, Boston

Sponsors
All Listed Sponsors
lead

Orca Biosystems, Inc.

INDUSTRY